Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03599843
Other study ID # 1023682
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2018
Est. completion date December 31, 2024

Study information

Verified date February 2023
Source Nova Scotia Health Authority
Contact Scott A Grandy, PhD
Phone 902-494-4303
Email grandy@dal.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cancer continues to have the dubious honor of being the leading cause of premature mortality in Canada. The good news is, advances in early detection and cancer treatments are extending the lives of those diagnosed with the disease. However, as more people are living longer, the impact of the therapies used to treat the disease are becoming increasingly apparent. Ranging from the physiological to psychological, cancer survivors are often confronted with substantial, disabling, and life-threatening consequences. The benefits of physical activity (all movement) and exercise more specifically have long been established as a means of prevention and treatment of chronic disease. Several recent reviews and meta-analyses have demonstrated that exercise is a safe and effective means of preventing and improving a multitude of physical and psychological treatment and disease-related sequelae across the cancer trajectory. For example, we know that cancer survivors who exercise not only have a reduced risk of disease recurrence and cancer mortality, but also have reduced acute/late effects of their cancer and/or its treatment such as anxiety, depression, and cancer-related pain. Regrettably, despite our substantial knowledge base, the majority of cancer survivors are not sufficiently active to realize these benefits over the long-term. Moreover, even with the development of evidence-based guidelines, exercise has not yet been widely implemented as a standard of care in the oncology setting largely due to a lack of resources, exercise expertise, and awareness of benefits. Continuing to provide cancer care with little guidance and understanding of the benefits of exercise places cancer survivors at an increased risk for recurrence, late effects, and/or onset of additional co-morbidities, and premature mortality. Therefore, it is important to consider best practices that will optimize and improve quality of survival. Building on the ongoing work of our Alberta-based colleagues and the Alberta Cancer Exercise (ACE) Program (an evidence-based clinic-to-community cancer exercise model), Activating Cancer Communities through an Exercise Strategy for Survivors (ACCESS) is designed to bridge the gap between research and practice and in doing so, lessen the impact of a cancer diagnosis and its treatment(s) on the physical and psychological well-being of cancer survivors.


Description:

Study Design: Type 2, hybrid implementation-effectiveness study The proposed project is strongly aligned with the multidisciplinary Alberta Cancer Exercise (ACE; Culos-Reed and McNeely, Co-PIs) lifestyle initiative - a result of the accumulation of over 15 years of research in the design, implementation and evaluation of cancer exercise programs. While the Alberta model has and will continue to be adapted to the Nova Scotia context, the utilization of a Canadian-based, integrated cancer exercise model, with demonstrated success and existing training resources will provide the much-needed framework to improve health outcomes in cancer patients/survivors. In brief, ACCESS will facilitate oncologist referral of survivors to a hospital-based, Certified Exercise Physiologist (CEP) as well as "Cancer Exercise Wise" certified community-based fitness professionals. The CEP will be responsible for screening and triaging survivors to assess participant interests and needs and to determine the appropriate level of activity and any supervision required to maximize benefits and ensure participant safety. Following screening the CEP will link the survivor with the appropriate hospital or community-based physical activity supports (see "TRIAGE PATHWAY"). Exercise programming will include aerobic, resistance, balance, and flexibility training and will be consistent with the exercise delivery model developed for ACE (www.albertacancerexercise.com). Participants will include adult cancer survivors of all cancers and stages at any point along the cancer care trajectory. Eligibility: Participants will be screened for eligibility and must: 1) Have a diagnosis of cancer; 2) Be 18+ years; 3) Be able to participate in mild levels of physical activity (at a minimum); 4) Be pre-treatment, receiving active treatment, or have received cancer treatment within the past 5 years or have a late presenting/ongoing side-effects related to the cancer diagnosis; 5) be willing to attend a 12-week exercise program in Halifax; and 5) Be able to provide informed written consent in English. A Certified Exercise Physiologist (CEP), housed within the QEII cancer care center (Halifax, NS), will have (medically approved) consenting participants complete a baseline PA and cancer specific screening measure to determine appropriateness/preferences for hospital and/or community-based PA participation. The CEP will oversee baseline physical fitness testing and will evaluate screening and testing results. The CEP will then triage the participant to a hospital or a local community-based fitness center depending on their cancer-related needs and programming preferences. The hospital site, under direct supervision of the CEP, will be used for those with identified cancer or other health-related needs that preclude exercising in a community-based setting. The community-based site will be supported by the CEP and will serve those participants cleared to exercise under a "Cancer and Exercise" trained fitness professional, but without high medical needs that would require direct CEP supervision. INTERVENTION: PA programming will be consistent with the exercise delivery models used in pilot programming both in Alberta and here in Halifax (EXACT) and will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group/individual personal training format, twice weekly, for 12-weeks. OUTCOME MEASURES: A mixed-methods approach will be used to assess study outcomes. Patient reported outcomes (effectiveness measures) will be assessed at baseline, post-intervention, 6 and 12 month follow-up. Implementation outcomes will be assessed throughout the duration of the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have a diagnosis of cancer; - Be 18+ years; - Be pre-treatment, receiving active treatment, or have received cancer treatment within the past 5 years or have a late presenting/ongoing side-effects related to the cancer diagnosis; - Be able to participate in mild levels of physical activity (at a minimum); - Be willing to attend a 12-week exercise program in Halifax; - Be able to provide informed written consent in English. Exclusion Criteria: - Less than 18 years of age.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise
Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.

Locations

Country Name City State
Canada QEII Health Sciences Centre (Dickson Bldg) Halifax Nova Scotia

Sponsors (1)

Lead Sponsor Collaborator
Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Physiological Outcome - resting heart rate Seated resting heart rate will be measured in beats per minute. 12 weeks
Primary Physiological outcome - blood pressure Seated systolic and diastolic blood pressure will be measured in mm of Hg 12 weeks
Primary Physiological outcome - 6 minute walk test (6MWT) The total distance walked in 6 minutes will be measured in meters 12 weeks
Primary Physiological Outcome - handgrip Handgrip will be measured in both the left and right hand. Two trials will be conducted on each side and the highest score will be used. Handgrip is measured in kg. 12 weeks
Primary Physiological outcome - timed sit-to-stand Time, is seconds, required to move from a seated to a standing position will be recorded. 12 weeks
Primary Physiological Outcome - one legged stance/balance Participants will be asked to stand on one leg with no support for as long as they can up to a maximum of 45 seconds. Trials will be conducted on the right and left side and time will be recorded in seconds. 12 weeks
Primary Physiological Outcome - sit-and-reach Hamstring flexibility will be measured in centimeters. 12 weeks
Primary Physiological Outcome - shoulder flexibility Shoulder flexibility will be measured in degrees 12 weeks
Primary Daily steps Total number of daily steps will be recorded using a pedometer. 12 weeks
Primary Functional Assessment of Cancer therapy General (FACT-G) The FACT-G is used to assess quality of life. It is a 27 item compilation of questions dived in four primary quality of life domains: 1) physical well-being; 2) social/family well-being; 3) emotional well-being; and 4) functional well-being. 12 weeks
Primary Physical Activity Behaviour The Godin Leisure Time Exercise Questionnaire will be used to assess physical activity and sedentary behaviour. 12 weeks
Primary Sleep Quality Sleep quality will be assessed using the Pittsburgh sleep quality index. 12 weeks
Primary Depression Anxiety Stress Scales (DASS) The depression anxiety stress scales consists of a list of 42 symptoms associated with depression, anxiety or stress. The participant is asked score the severity of the symptom over the past week on a 4 point scale. 12 weeks
Primary Fatigue The functional assessment of chronic illness therapy-fatigue (FACIT-F), which is a 13-item scale, will be used to assess participant levels of fatigue. 12-weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases